Frontotemporal dementia (FTD) is the second most common type of presenile dementia. Three clinical prototypes have been defined; behavioral variant FTD, semantic dementia, and progressive nonfluent aphasia. Progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease may possess clinical and pathological characteristics that overlap with FTD, and it is possible that they may all belong to the same clinicopathological spectrum. Frontotemporal lobar degeneration (FTLD) is a clinicopathological syndrome that encompasses a heterogenous group of neurodegenerative disorders. Owing to the advancement in the field of molecular genetics, diagnostic imaging, and pathology, FTLD has been the focus of great interest. Nevertheless, parkinsonism in FTLD has received relatively less attention. Parkinsonism is found in approximately 20–30% of patients in FTLD. Furthermore, parkinsonism can be seen in all FTLD subtypes, and some patients with familial and sporadic FTLD can present with prominent parkinsonism. Therefore, there is a need to understand parkinsonism in FTLD in order to obtain a better understanding of the disease. With regard to the clinical characteristics, the akinetic rigid type of parkinsonism has predominantly been described. Parkinsonism is frequently observed in familial FTD, more specifically, in FTD with parkinsonism linked to chromosome 17q (FTDP-17). The genes associated with parkinsonism are microtubule associated protein tau (MAPT), progranulin (GRN or PGRN), and chromosome 9 open reading frame 72 (C9ORF72) repeat expansion. The neural substrate of parkinsonism remains to be unveiled. Dopamine transporter (DAT) imaging revealed decreased uptake of DAT, and imaging findings indicated atrophic changes of the basal ganglia. Parkinsonism can be an important feature in FTLD and, therefore, increased attention is needed on the subject.

Citations

Citations to this article as recorded by  

• Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
  Harry Costello, Jonathan P. Roiser, Robert Howard
  Psychological Medicine.2023; 53(3): 654.     CrossRef
• Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
  Luigi Fiondella, Priya Gami-Patel, Christian A. Blok, Annemieke J. M. Rozemuller, Jeroen J. M. Hoozemans, Yolande A. L. Pijnenburg, Marta Scarioni, Anke A. Dijkstra
  Acta Neuropathologica Communications.2023;[Epub]     CrossRef
• Demencias degenerativas: ¿un dilema de síndromes o de enfermedades?
  A. Robles Bayón
  Neurología.2022; 37(6): 480.     CrossRef
• Degenerative dementias: a question of syndrome or disease?
  A. Robles Bayón
  Neurología (English Edition).2022; 37(6): 480.     CrossRef
• Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration—Insights into disease mechanisms and current therapeutic approaches
  Nadine Huber, Sonja Korhonen, Dorit Hoffmann, Stina Leskelä, Hannah Rostalski, Anne M. Remes, Paavo Honkakoski, Eino Solje, Annakaisa Haapasalo
  Molecular Psychiatry.2022; 27(3): 1300.     CrossRef
• Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism
  Murat Gultekin, Zeynep Tufekcioglu, Recep Baydemir
  Neurocase.2022; 28(1): 107.     CrossRef
• Dopamine Transporter Imaging for Frontotemporal Lobar Degeneration With Motor Neuron Disease
  Ryota Kobayashi, Shinobu Kawakatsu, Makoto Ohba, Daichi Morioka, Masafumi Kanoto, Koichi Otani
  Frontiers in Neuroscience.2022;[Epub]     CrossRef
• Investigational therapeutics for the treatment of progressive supranuclear palsy
  David G Coughlin, Irene Litvan
  Expert Opinion on Investigational Drugs.2022; 31(8): 813.     CrossRef
• Frequency and Longitudinal Course of Motor Signs in Genetic Frontotemporal Dementia
  Sonja Schönecker, Francisco J. Martinez-Murcia, Boris-Stephan Rauchmann, Nicolai Franzmeier, Catharina Prix, Elisabeth Wlasich, Sandra V. Loosli, Katja Bochmann, Juan-Manuel Gorriz Saez, Robert Laforce, Simon Ducharme, Maria Carmela Tartaglia, Elizabeth F
  Neurology.2022;[Epub]     CrossRef
• Multi-Modal Synergistic 99mTc-TRODAT-1 SPECT and MRI for Evaluation of the Efficacy of Hyperbaric Oxygen Therapy in CO-Induced Delayed Parkinsonian and Non-Parkinsonian Syndromes
  Skye Hsin-Hsien Yeh, Chuang-Hsin Chiu, Hung-Wen Kao, Ching-Po Lin, Yu-Hus Lai, Wen-Sheng Huang
  Antioxidants.2022; 11(11): 2289.     CrossRef
• Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
  Jun Yup Lee, Oana C. Marian, Anthony S. Don
  NeuroMolecular Medicine.2021; 23(1): 1.     CrossRef
• Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases
  Daisy Sproviero, Stella Gagliardi, Susanna Zucca, Maddalena Arigoni, Marta Giannini, Maria Garofalo, Martina Olivero, Michela Dell’Orco, Orietta Pansarasa, Stefano Bernuzzi, Micol Avenali, Matteo Cotta Ramusino, Luca Diamanti, Brigida Minafra, Giulia Peri
  International Journal of Molecular Sciences.2021; 22(5): 2737.     CrossRef
• Parkin beyond Parkinson’s Disease—A Functional Meaning of Parkin Downregulation in TDP-43 Proteinopathies
  Katarzyna Gaweda-Walerych, Emilia Jadwiga Sitek, Ewa Narożańska, Emanuele Buratti
  Cells.2021; 10(12): 3389.     CrossRef
• Joint contractures and acquired deforming hypertonia in older people: Which determinants?
  Patrick Dehail, Nathaly Gaudreault, Haodong Zhou, Véronique Cressot, Anne Martineau, Julie Kirouac-Laplante, Guy Trudel
  Annals of Physical and Rehabilitation Medicine.2019; 62(6): 435.     CrossRef
• Review: Clinical, genetic and neuroimaging features of frontotemporal dementia
  R. Convery, S. Mead, J. D. Rohrer
  Neuropathology and Applied Neurobiology.2019; 45(1): 6.     CrossRef
• Granulin in Frontotemporal Lobar Degeneration: Molecular Mechanisms of the Disease
  Zemfira N. Karamysheva, Elena B. Tikhonova, Andrey L. Karamyshev
  Frontiers in Neuroscience.2019;[Epub]     CrossRef
• The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia
  Yangqi Xu, Xiaoli Liu, Junyi Shen, Wotu Tian, Rong Fang, Binyin Li, Jianfang Ma, Li Cao, Shengdi Chen, Guanjun Li, Huidong Tang
  Aging and disease.2018; 9(4): 696.     CrossRef
• Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology
  Rebekah M. Ahmed, Muireann Irish, Janet van Eersel, Arne Ittner, Yazi D. Ke, Alexander Volkerling, Julia van der Hoven, Kimi Tanaka, Tim Karl, Michael Kassiou, Jillian J. Kril, Olivier Piguet, Jürgen Götz, Matthew C. Kiernan, Glenda M. Halliday, John R. H
  Neuroscience & Biobehavioral Reviews.2017; 74: 126.     CrossRef
• Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases
  Anne-Claire Dupont, Bérenger Largeau, Maria Santiago Ribeiro, Denis Guilloteau, Claire Tronel, Nicolas Arlicot
  International Journal of Molecular Sciences.2017; 18(4): 785.     CrossRef
• Intrinsic functional connectivity alterations in progressive supranuclear palsy: Differential effects in frontal cortex, motor, and midbrain networks
  Johannes Rosskopf, Martin Gorges, Hans‐Peter Müller, Dorothée Lulé, Ingo Uttner, Albert C. Ludolph, Elmar Pinkhardt, Freimut D. Juengling, Jan Kassubek
  Movement Disorders.2017; 32(7): 1006.     CrossRef
• Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred
  Gianluca Floris, Giuseppe Borghero, Francesca Di Stefano, Rosanna Melis, Roberta Puddu, Laura Fadda, Maria R. Murru, Daniela Corongiu, Stefania Cuccu, Stefania Tranquilli, Antonino Cannas, Maria G. Marrosu, Adriano Chiò, Francesco Marrosu
  Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2016; 17(3-4): 245.     CrossRef
• Clinical features ofTBK1carriers compared withC9orf72,GRNand non-mutation carriers in a Belgian cohort
  Sara Van Mossevelde, Julie van der Zee, Ilse Gijselinck, Sebastiaan Engelborghs, Anne Sieben, Tim Van Langenhove, Jan De Bleecker, Jonathan Baets, Mathieu Vandenbulcke, Koen Van Laere, Sarah Ceyssens, Marleen Van den Broeck, Karin Peeters, Maria Mattheijs
  Brain.2016; 139(2): 452.     CrossRef
• Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis
  Carmen Gasca-Salas, Mario Masellis, Edwin Khoo, Binit B. Shah, David Fisman, Anthony E. Lang, Galit Kleiner-Fisman, Patrick Lewis
  PLOS ONE.2016; 11(4): e0153852.     CrossRef
• The clinical spectrum of sporadic and familial forms of frontotemporal dementia
  Ione O. C. Woollacott, Jonathan D. Rohrer
  Journal of Neurochemistry.2016; 138(S1): 6.     CrossRef
• Genetics of Progressive Supranuclear Palsy
  Sun Young Im, Young Eun Kim, Yun Joong Kim
  Journal of Movement Disorders.2015; 8(3): 122.     CrossRef

Apomorphine is a well established treatment for the management of sudden, unexpected and refractory levodopa-induced “off” states in fluctuating Parkinson’s disease either as bolus injections or as continuous infusions. Incidents of atrial fibrillation associated with the administration of the drug have been reported in the past but no incidents of ventricular arrhythmias. We report a case of ventricular bigeminy recorded in a female patient after the administration of apomorphine.

Citations

Citations to this article as recorded by  

• Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance
  Luca Marsili, Matteo Bologna, Janis M. Miyasaki, Carlo Colosimo
  Parkinsonism & Related Disorders.2021; 83: 132.     CrossRef
• Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease
  Mohammad Al Majali, Michael Sunnaa, Pratap Chand
  Journal of Geriatric Psychiatry and Neurology.2021; 34(4): 263.     CrossRef
• Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
  Martin Klietz, Stephan Greten, Florian Wegner, Günter U. Höglinger
  Drugs & Aging.2019; 36(6): 511.     CrossRef
• Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance
  Manon Auffret, Sophie Drapier, Marc Vérin
  Clinical Drug Investigation.2018; 38(4): 287.     CrossRef
• Cardiac abnormalities in Parkinson’s disease and Parkinsonism
  Fulvio A. Scorza, Ana C. Fiorini, Carla A. Scorza, Josef Finsterer
  Journal of Clinical Neuroscience.2018; 53: 1.     CrossRef
• Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue pharmacologique
  M. Auffret, S. Drapier, M. Vérin, P. Sauleau
  Pratique Neurologique - FMC.2016; 7(1): 25.     CrossRef
• Practical management of adverse events related to apomorphine therapy
  Roongroj Bhidayasiri, Pedro J. Garcia Ruiz, Tove Henriksen
  Parkinsonism & Related Disorders.2016;[Epub]     CrossRef

Isolated middle cerebral artery (MCA) stenosis in young patients with no other medical condition may be a unique pathologic entity with a benign long-term course. Generally, moyamoya disease shows a progression of stenosis from internal cerebral artery (ICA) to other intracranial vessel. A 26-year-old woman was admitted for choreic movements of the right arm and leg. Brain magnetic resonance imaging showed no stroke. Conventional angiography revealed 48% stenosis of the left M1 without ICA stenosis. Single photon emission computed tomography revealed perfusion asymmetry after acetazolamide injection, suggesting decreased uptake in the left basal ganglia and the cerebral cortex. Her hemichorea was mildly decreased with risperidone. One year later, follow-up angiography showed complete occlusion of the left M1 with neovascularization suggestive of moyamoya disease. The patient underwent bypass surgery and her hemichorea disappeared. This may be an atypical presentation of moyamoya disease. The bypass surgery was an effective measure for restoring the vascular insufficiency and, resultantly, controlling her hemichorea.

Citations

Citations to this article as recorded by  

• Hemichorea in patients with temporal lobe infarcts: Two case reports
  Xu-Dong Wang, Xing Li, Chun-Lian Pan
  World Journal of Clinical Cases.2024; 12(4): 806.     CrossRef
• Truncal dystonia with isolated middle cerebral artery ischemia: A case report of revascularization therapy for dystonia
  Shinichi Matsumoto, Yuki Yamamoto, Koji Fujita, Ryosuke Miyamoto, Hidetaka Koizumi, Akihiro Tateishi, Naoaki Yamada, Yuishin Izumi
  Surgical Neurology International.2022; 13: 155.     CrossRef
• Geriatric Case of Moyamoya Disease Presenting with Hemiballismus as an Initial Manifestation
  Koichiro SATO, Masaru IDEI, Kenichirou NOGAMI, Makoto KURESHIMA, Kaname HOKAO, Rina TORII, Takenori UOZUMI, Junkoh YAMAMOTO
  Surgery for Cerebral Stroke.2022; 50(6): 508.     CrossRef
• Persistent Hemichorea as a Preceding Symptom of Cerebral Infarction Due to Middle Cerebral Artery Stenosis
  Yuki Ueta, Haruhisa Kato, Makiko Naito, Takeshi Taguchi, Hiroo Terashi, Hitoshi Aizawa
  Internal Medicine.2021; 60(23): 3805.     CrossRef
• Clinical findings of a patient with hemiballism after superficial temporal artery-middle cerebral artery anastomosis for idiopathic middle cerebral artery stenosis
  Hideaki Shibata, Yuichi Hayashi, Nobuaki Yoshikura, Megumi Yamada, Akio Kimura, Takayoshi Shimohata
  Rinsho Shinkeigaku.2019; 59(12): 829.     CrossRef

Involuntary movement associated with deep watershed ischemic lesions has been rarely reported. A 67-year-old woman presented with acute hemichorea on the left side. Magnetic resonance imaging showed acute infarcts in the anterior border zone. On perfusion studies, impaired cerebral blood flow was observed on the subcortical region sparing the basal ganglia. Cerebral angiogram confirmed severe stenosis in the right internal carotid artery. Her hemichorea gradually improved along with normalization of perfusion after carotid artery stenting with angioplasty. We suggest that impaired cerebral blood flow in critical watershed territories may be an important contributing factor in hemichorea associated with carotid occlusive disease.

Citations

Citations to this article as recorded by  

• Hemichorea associated with subcortical border-zone infarction and middle cerebral artery stenosis
  So-Ei Ann, Suho Ro, Yun Hyeong Jeong, Sumin Kim, Pil-Wook Chung
  Journal of Geriatric Neurology.2022; 1(1): 41.     CrossRef
• Movement Disorders Associated With Cerebral Artery Stenosis: A Nationwide Study
  Kye Won Park, Nari Choi, Eungseok Oh, Chul Hyoung Lyoo, Min Seok Baek, Han-Joon Kim, Dalla Yoo, Jee-Young Lee, Ji-Hyun Choi, Jae Hyeok Lee, Seong-Beom Koh, Young Hee Sung, Jin Whan Cho, Hui-Jun Yang, Jinse Park, Hae-Won Shin, Tae-Beom Ahn, Ho-Sung Ryu, So
  Frontiers in Neurology.2022;[Epub]     CrossRef
• Hemiballism-hemichorea revealing carotidal stenosis
  I. Ion, T. Parvu, G. Farouil, D. Sablot
  Revue Neurologique.2022; 178(8): 859.     CrossRef
• The Impact of Revascularization in a Patient with Atypical Manifestations of Hypoperfusion
  Sintija Strautmane, Zanda Priede, Andrejs Millers
  Medicina.2022; 58(10): 1328.     CrossRef
• A case of hemichorea in RNF213-related vasculopathy
  Satoshi Hosoki, Takeshi Yoshimoto, Masafumi Ihara
  BMC Neurology.2021;[Epub]     CrossRef
• Acute hemichorea with T1 ischemic hyperintensity associated with steno‐occlusive middle cerebral artery dissection
  Yong Chuan Chee, Beng Hooi Ong
  Neurology and Clinical Neuroscience.2020; 8(1): 44.     CrossRef
• A case of hemichorea caused by right internal carotid artery stenosis
  Kazuki Muguruma, Atsuko Motoda, Takamichi Sugimoto, Takeshi Kitamura
  Rinsho Shinkeigaku.2019; 59(8): 509.     CrossRef
• Movement Disorders Following Cerebrovascular Lesions: Etiology, Treatment Options and Prognosis
  Do-Young Kwon
  Journal of Movement Disorders.2016; 9(2): 63.     CrossRef
• Hemichorea improvement following endarterectomy for internal carotid artery stenosis
  Kazuyuki Noda, Reo Ishimoto, Nobutaka Hattori, Yasuyuki Okuma, Takuji Yamamoto
  Journal of the Neurological Sciences.2016; 371: 45.     CrossRef
• Hemichorea Resulting from Ischemic Stroke in the Ipsilateral Caudate Nucleus
  Seung-Keun Lee, Ji Sun Kim, Kyung-Bok Lee, Hakjae Roh, Moo-young Ahn
  Journal of Neurocritical Care.2015; 8(2): 109.     CrossRef

There were few cases of thrombocytopenia associated with levodopa. Herein, we report a patient with Parkinson’s disease, who suffered thrombocytopenia related to long-term use of levodopa.

Citations

Citations to this article as recorded by  

• A 70-year-old male exhibiting parkinsonism-hyperpyrexia syndrome during levodopa carbidopa intestinal gel (LCIG) treatment and suspected carbidopa allergy due to positive drug-induced lymphocyte stimulation test (DLST)
  Aya Kawanami, Masanobu Miyashita, Yuichi Miyagi, Kazuko Hasegawa
  Rinsho Shinkeigaku.2024; 64(1): 17.     CrossRef
• High rates of blood transfusion associated with Parkinson’s disease
  Shane Shahrestani, Julian Gendreau, Ali R. Tafreshi, Nolan J. Brown, Khashayar Dashtipour
  Neurological Sciences.2022; 43(8): 4761.     CrossRef
• Platelet abnormalities in patients with Parkinson's disease undergoing preoperative evaluation for deep brain stimulation
  Sheng-Che Chou, Chun-Hwei Tai, Sheng-Hong Tseng
  Scientific Reports.2022;[Epub]     CrossRef